US 11,896,619 B2
Compositions and methods for immunotherapy of NPM1c-positive cancer
Jianzhu Chen, Lexington, MA (US); and Guozhu Xie, Cambridge, MA (US)
Assigned to Massachusetts Institute of Technology, Cambridge, MA (US)
Filed by Massachusetts Institute of Technology, Cambridge, MA (US)
Filed on Jan. 8, 2021, as Appl. No. 17/144,834.
Claims priority of provisional application 62/987,612, filed on Mar. 10, 2020.
Prior Publication US 2021/0283178 A1, Sep. 16, 2021
Int. Cl. A61K 35/17 (2015.01); A61P 35/04 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01)
CPC A61K 35/17 (2013.01) [A61P 35/04 (2018.01); C07K 16/2818 (2013.01); C07K 16/3061 (2013.01)] 82 Claims
OG exemplary drawing
 
1. An antibody, or antigen binding fragment thereof, that specifically binds to an antigen comprising an NPM1c neoepitope in complex with a class I major histocompatibility complex (MHC class I) protein, wherein the antibody, or antigen binding fragment comprises:
(a) a heavy chain variable region (VH), wherein the VH comprises VH complementarity determining region (CDR)1, VH CDR2 and VH CDR3, wherein the VH CDR1 has the amino acid sequence GFTFSSYA (SEQ ID NO:9), the VH CDR2 has the amino acid sequence ISGSGGST (SEQ ID NO:10), and the VH CDR3 has the amino acid sequence ARLGYPTTTLLPFDY (SEQ ID NO:11); and
(b) a light chain variable region (VL), wherein the VL comprises VL complementarity determining region (CDR)1, VL CDR2 and VL CDR3, wherein the VL CDR1 has the amino acid sequence QSISSY (SEQ ID NO:6), the VL CDR2 has the amino acid sequence AAS (SEQ ID NO:7), and the VL CDR3 has the amino acid sequence QQSYSTPLT (SEQ ID NO:8).